Holen Sie sich die Stockscreener-App
18.93
5.17%
0.93
Schlusskurs vom Vortag:
$18.00
Offen:
$18.3
24-Stunden-Volumen:
156.86K
Relative Volume:
0.90
Marktkapitalisierung:
$617.95M
Einnahmen:
Nettoeinkommen (Verlust:
$-29.59M
KGV:
-14.85
EPS:
-1.275
Netto-Cashflow:
$-18.35M
1W Leistung:
-5.96%
1M Leistung:
-13.64%
6M Leistung:
+122.71%
1J Leistung:
+210.84%
1-Tages-Spanne:
$18.30
$19.59
1-Wochen-Bereich:
$17.68
$21.29
52-Wochen-Spanne:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
18.93 | 617.95M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 - Yahoo Finance
NVCT: Strong clinical progress and financial position drive near-term catalysts in precision medicine - TradingView
Nuvectis at Cantor healthcare conference: betting on factor B By Investing.com - Investing.com Canada
NVCT: NXP100's once-daily dosing and strong efficacy position it to disrupt the PNH market - TradingView
Nuvectis at Cantor healthcare conference: betting on factor B - investing.com
NVCT: NXP100's once-daily dosing and strong PNH data position it for pivotal U.S. trials and expansion - TradingView
Nuvectis Pharma, Inc. (NVCT) Stock Price & News - Syfe
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Nuvectis Pharma To Participate in Upcoming Investor Conferences - Investing News Network
Nuvectis Pharma plans two September talks, both available online - Stock Titan
Nuvectis Pharma To Participate in Upcoming Investor Conferences - GlobeNewswire
Nuvectis Pharma (NVCT) Rises 3.75% to $23.93, Pressing Against Key ResistanceHigh Volume Stocks - vinanet.vn
Lucid Capital Markets initiates Nuvectis Pharma stock with buy rating By Investing.com - Investing.com UK
Nuvectis Pharma Inc (NVCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvectis Pharma, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - qz.com
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - easternprogress.com
Nuvectis Pharma Launches New $200 Million ATM Program - TipRanks
Nuvectis Pharma (Nasdaq: NVCT) sets at-the-market stock sales capacity - Stock Titan
Nuvectis Pharma (NASDAQ: NVCT) sets at-the-market share sales via Jefferies - Stock Titan
Nuvectis (NVCT): Moves 0.26% Down to $23.29; Boundary Watch: $22.13 and $24.45 Define the Nearby Reference Levels in the Latest SessionProfit Surge Picks - vinanet.vn
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate - Sahm
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate - simplywall.st
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate - simplywall.st
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why - Yahoo Finance
Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% HigherWhat's Next? - MarketBeat
Nuvectis Pharma (NVCT) Slips 1.4% to $18.96 as Shares Approach Key Support LevelALMA Signal - vinanet.vn
Behavioral Patterns of NVCT and Institutional Flows - Stock Traders Daily
Nuvectis Pharma (NVCT) Slips 1.4% to $18.96 as Shares Approach Key Support LevelEarnings Quality Factor - siam.in
NVCT Q2 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline ProgressesInvestor Earnings Call - vinanet.vn
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap UpWhat's Next? - MarketBeat
NVCT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued R&D InvestmentPre-Earnings Setup - vinanet.vn
NVCT Q2 2026 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Investment PhaseShare Dilution Risk - vinanet.vn
Certain Stock Options of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Nuvectis Pharma (NVCT) Holds Near $18.88 as Shares Consolidate Between Support and ResistanceSupport Level Bounce - vinanet.vn
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline Amid Ongoing Clinical Development - vinanet.vn
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market Wi - The National Law Review
Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next - TipRanks
Soleus group (NVCT) discloses 1.65M-share, 5.1% Nuvectis Pharma stake - Stock Titan
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma - MarketBeat
(NVCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical Risks - TipRanks
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss - MarketBeat
Nuvectis Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvectis Pharma, Inc. 2Q 2026: Net loss $(7.02)M, EPS $(0.30) — 10-Q Summary - TradingView
NVCT: Q2 2026 net loss widened to $7.0M; $106.3M raised in July extends cash runway for clinical development - TradingView
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
5.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):